Prospective Assessment of Acute Skin Toxicities in Breast Cancer Patients Undergoing Retreatment with 40 Gy in 15 Fractions Radiation Therapy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The most common cancer affecting Canadian women is breast cancer, with an estimated 1 in 8 women expected to be diagnosed with breast cancer during their lifetime. Improved screening and treatment have decreased mortality of breast cancer patients, however 14% of cancer-related deaths in Canadian women are still due to breast cancer. Common treatments for breast cancer include surgery, chemotherapy, hormone therapy, and radiation therapy (RT). Despite recent improvements in treatment and preventative screenings, 20% of breast cancer patients will develop local disease recurrence or another ipsilateral primary breast cancer. . The optimal treatment of recurrent or new primary breast cancers for patients who have undergone prior radiotherapy (RT) is not well-defined. Common treatment approaches consist of mastectomy or a second breast conserving surgery (BCS) with whole or partial breast reirradiation (reRT). In the past, mastectomy has been the preferred treatment for recurrent breast cancer due to concerns over serious acute and late skin toxicities that may result from additional reRT. Many of these late skin toxicities, such as fibrosis, are chronic and can result in patients experiencing pain or other negative impacts to quality of life (QOL).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years old

• Informed consent

• Histological confirmation of breast malignancy (invasive or in situ carcinoma) or phyllodes

• Previous history of ipsilateral breast cancer treated with RT

• Patients are planned to receive hypofractionated (40Gy/15) RT to the whole or partial breast or chest wall

• Patients treated with or without the addition of a planned boost or bolus

• Patients receiving local or locoregional radiation treatment

• Can communicate in English or be aided by a translator

Locations
Other Locations
Canada
Odette Cancer Center Sunnybrook Health Sciences Centre
RECRUITING
Toronto
Contact Information
Primary
Irene Karam, MDCM
Irene.karam@sunnybrook.ca
416-480-4974
Backup
Edward Chow, MBBS
edward.chow@sunnybrook.ca
416-480-4974
Time Frame
Start Date: 2024-08-07
Estimated Completion Date: 2026-08-07
Participants
Target number of participants: 30
Related Therapeutic Areas
Sponsors
Leads: Sunnybrook Health Sciences Centre

This content was sourced from clinicaltrials.gov